Algernon Health Inc., formerly Algernon Pharmaceuticals Inc., is a Canadian healthcare company. The Company is focused on the provision of brain-specific PET scanning services through a planned network of new clinics in North America for the early-stage detection of Alzheimer’s disease, as well as other forms of dementia, epilepsy, neuro-oncology, and movement disorders. It is also the parent company of a private subsidiary called Algernon NeuroScience that has been advancing a psychedelic program investigating a proprietary form of DMT for stroke and traumatic brain injury recovery. The Company also owns a 20% equity position in Seyltx, a private U.S-based drug development company advancing a chronic cough drug called Ifenprodil.

• Revenue in CAD (TTM)0.00
• Net income in CAD-1.93m
• Incorporated2015
• Employees--

• Location
  Algernon Health IncSuite 400 - 601 West BroadwayVANCOUVER V5Z 4C2CanadaCAN
• Phone+1 (604) 398-4175
• Fax+1 (604) 646-1553
• Websitehttps://algernonpharmaceuticals.com